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Adipose tissue is a kind of connective tissue. It is a highly specialized tissue that 
plays a significant role in humans and animals. Adipocytes, cells of adipose tissue, 
store lipids and triacylglycerol as well as synthesize fatty acids. It also protects 
against mechanical injury as well as against cold. Adipose tissue is also involved in 
process of thermogenesis. Adipose tissue is also a metabolic active organ. Adipose 
tissue, beside adipocytes, contains also the stromal vascular fraction (SVF) of cells 
including fibroblasts, vascular endothelial cells, and immune cells, for example, 
macrophages.
2. Types of adipose tissue
Based on colors, adipose tissue is classified as white adipose tissue (WAT) and 
brown adipose tissue (BAT). These two types of adipocytes arise from separate 
progenitor cell lines. They show distinct morphology, structure, localization in the 
body, and function [1, 2].
White adipocytes are globular cells. Their size varies between 25 and 200 μm and 
depends on the size of the single lipid droplet accumulated within them [3, 4]. They 
contain large, single lipid droplet, more than 90% of the cell volume. Therefore, the 
amount of cytoplasm is small, and the nucleus is decentralized [5] and has a low 
density of mitochondria [3, 4]. Their main function is to store lipids, as energetic 
molecules to provide energy to the cells between the meals. White adipose tissue 
secretes also several molecules, such as retinol, steroid, hormones, prostaglandins, 
and adipokines that are pro- and anti-inflammatory cytokines. These molecules 
influence human and animal physiology and pathology.
White adipose tissue may be differentiated based on the anatomical locations 
or depots: subcutaneous (under the skin in the hypodermis region) and visceral. 
Increased visceral fat increases the risk of metabolic and cardiovascular diseases 
[6, 7]. Subcutaneous fat may protect against metabolic derangements [8]. Two 
subcutaneous fat regions in humans are recognized: upper and lower body fat. 
Accumulation of fat in lower regions (around the gluteal and femoral, the so-called 
gluteofemoral regions) improves glucose tolerance [9], negatively correlates with 
insulin resistance [8], and is associated with reduced aortic calcification [10]. 
Visceral adipose tissue is generally regarded as intra-abdominal adipose tissue. 
Visceral fat surrounds the internal organs. The major visceral depots are the 
omental, retroperitoneal, perineal, mesenteric, and pericardial depots [11, 12]. The 
mesenteric and omental adipose tissues drain directly into the portal circulation. 
These adipocytes release free fatty acids and pro-inflammatory cytokines to the 
liver. This process causes the development of hepatic steatosis and insulin resistance 
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[13, 14]. Pericardial fat increases the risk of metabolic disorders and low-grade 
inflammation, involved in type 2 diabetes and cardiac complication. It may cause 
also increased diastolic pressure and fasting insulin levels [15, 16] and arterial 
calcium accumulation [17] and severity of coronary disease [18]. Increased perire-
nal and pararenal depots are associated with glomerulopathy [19], chronic kidney 
diseases in patients with type 2 diabetes [20], and hypertension [21, 22]. Increased 
thickness of mesenteric fat is correlated with increased risk of cardiovascular 
diseases [23], Crohn’s disease [24], hepatic insulin resistance, and hepatosteatosis 
[25]. These observations suggest that increased visceral fat deposition is associated 
with diseases and metabolic derangements, whereas subcutaneous fat deposition is 
not so dangerous.
Brown adipose tissues have polygonal shape, and their diameter is variable. 
They are smaller in comparison to WAT (15–60 μm) [26]. They also contain lipid 
droplets, but as multiple, small vacuoles of varied size. These cells contain a large 
amount of cytoplasm and centralized nucleus [5]. The most characteristic organ-
elles presented in brown adipocytes are the mitochondria [27, 28]. BAT is found in 
fetuses and newborn, whereas in adult humans is practically absent. It is present at 
discrete sites such as in the upper trunk [29].
Recently, the third type of adipose tissue has been described. It is termed 
“brown-in-white,” “brite,” or “beige” [26, 30]. Beige adipose tissue histologically is 
very similar to BAT. The development of beige AT is due to the browning of WAT. It 
is an adaptive response to stimulation, for example, cold exposure, exercise, natri-
uretic peptides, thyroid hormones, bile acids, and so on [31–33]. Beige AT exhibits 
several intermediate features between BAT and WAT. For example, its adipocytes 
have a predominant lipid vacuole in the cytoplasm and numerous mitochondria 
[27, 34]. They express genes involved in the process of thermogenesis [30, 32, 33]. 
On the other hand, adipocytes of beige AT express characteristic and distinct gene 
markers. These gene markers are specific for beige adipocytes and distinguish them 
from adipocytes of BAT and WAT [26, 30, 35, 36].
3. Adipose tissue as an endocrine organ
As mentioned earlier, adipose tissue is also an endocrine organ. It secretes 
several hormones that regulate the homeostasis. The first molecule with hormonal 
activity secreted by adipocytes was leptin. It is a satiety hormone that suppresses 
food intake and increases energy expenditure. The levels of leptin are positively 
correlated with the amount of body fat [37]. Subcutaneous white adipose tissue 
secretes greater amounts of leptin than visceral WAT [38, 39]. Adiponectin, another 
hormone secreted by adipose tissue, is secreted primarily by subcutaneous rather 
than visceral fat. It shows anti-inflammatory and insulin-sensitizing roles [40]. In 
obese humans and patients with insulin resistance, the level of adiponectin is low 
[41, 42]. Resistin, a peptide hormone, impairs glucose and insulin metabolism and 
is implicated in insulin resistance [43, 44]. Visfatin is a hormone implicated in the 
utilization of glucose, predominantly synthesized and secreted in visceral fat [45]; 
however, it is predominantly secreted from macrophages rather than adipocytes. It 
has endocrine, paracrine, and autocrine functions and can bind to insulin receptor. 
There are also other hormones synthesized and secreted by adipose tissue such as 
acylation-stimulating protein (ASP) which is concerned with fat storage.
Adipose tissue secretes also growth factors, such as fibroblast growth fac-
tors (FGFs), insulin-like growth factor-1 (IGF-1), hepatocyte growth factor 
(HGF), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), 
and transforming growth factor (TGF). These growth factors stimulate several 
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processes such as adipogenesis [46], glucose metabolism [47], angiogenesis [48, 
49], and thermogenesis [50]. On the other hand, some of these growth factors may 
be a pro-inflammatory adipokines. Adipose tissue secretes also other inflammatory 
cytokines such as interleukin-6, interleukin-8, interferon-γ, plasminogen activa-
tion inhibitor-1 as well as anti-inflammatory adipokines, such as adiponectin [51]. 
There are also many other molecules secreted by adipose tissue, such as retinol-
binding protein 4 (RBP4), vaspin, omentin, chemerin, serum amyloid A (SAA), 
angiotensinogen, macrophage migration inhibitory factor (MIF), lipoprotein lipase, 
cholesterol ester transfer protein (CETP), prostaglandins, estrogens, glucocorti-
coids, and so on. All of these molecules influence human and animal processes. 
They have positive, as well as negative, effects on human health. Adipose tissue may 
be involved in the development of many diseases, such as type 2 diabetes mellitus 
[52, 53], metabolic syndrome [54], and several cancers (breast [55], cervical [56], 
endometrial [57], kidney [58], and gastrointestinal [59, 60]). Disturbances in func-
tions of adipose tissue may cause also psychiatric diseases and disorders, such as 
depression [61], dementia [62], insomnia [63], and many others.
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